When was Kodiak Sciences founded?

Kodiak Sciences was founded in 2009 and raised its 1st funding round within a year of its incorporation.

Where is Kodiak Sciences located?

Kodiak Sciences is headquartered in Palo Alto, United States. It is registered at Palo Alto (United States).

How many employees does Kodiak Sciences have?

As of Sep 30, 2026, the latest employee count at Kodiak Sciences is 135.

Is Kodiak Sciences a funded company?

Kodiak Sciences is a funded company, having raised a total of $35.8M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 21, 2009.

When was the latest funding round of Kodiak Sciences?

Kodiak Sciences' latest funding was a $***** Conventional Debt round on Apr 26, 2018, with participation from 2 investors.

Where does Kodiak Sciences rank among its competitors?

Kodiak Sciences ranks 73rd amongst 2831 active competitors, of which 950 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kodiak Sciences?

Kodiak Sciences' top competitors include Jazz Pharmaceuticals, argenx and Alexion. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kodiak Sciences - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of therapeutics to treat retinal diseases. The company has two drugs in the developmental stage includes KSI 301 for Age-related macular degeneration (AMD) and KSI 501 for Dry AMD. KSIs are built on proprietary science antibody bioconjugate product platforms.

Website: kodiak.com
Social
Registered Address: Palo Alto (United States)

Key Metrics

Founded Year

2009

Location

Palo Alto, United States

Stage

Public

Total Funding

$35.8M in 3 rounds

Latest Funding Round

Conventional Debt, Apr 26, 2018, $*****

Investors

ArrowMark Partners & 2 more

Ranked

73^rd among 2831 active competitors

Employee Count

135 as on Sep 30, 2026

Similar Companies

argenx & 531 more

Exit Details

Public

View Kodiak Sciences' full profile

Kodiak Sciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kodiak Sciences Valais GmbH CIN: 1433504 , Switzerland, Active	Apr 21, 2020	-	-	-
Kodiak Sciences Inc. CIN: 27-0476525 , United States, Active	Dec 31, 2008	-	112 (As on Dec 31, 2022)	-

Kodiak Sciences got listed on Oct 04, 2018.

Click here to take a look at Kodiak Sciences's IPO in detail

Kodiak Sciences has raised a total funding of $35.8M over 3 rounds. Its first funding round was on Jul 21, 2009. Its latest funding round was a Conventional Debt round on Apr 26, 2018 for $*****. 2 investors participated in its latest round. Kodiak Sciences has 3 institutional investors.

Here is the list of recent funding rounds of Kodiak Sciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 26, 2018	7881043	Conventional Debt	3341287	5906615	3925608	9511825
Mar 23, 2016	9401356	Series B	1751579	4475023	3567207	1450343
Jul 21, 2009	5466671	Seed	1831699	5635970	1315930	7191481

Access funding benchmarks and valuations. Sign up today!

View details of Kodiak Sciences's funding rounds and investors

Kodiak Sciences' employee count trend

Kodiak Sciences has 135 employees as of Sep 26. Here is Kodiak Sciences's employee count trend over the years:

Employee count trend for Kodiak Sciences

Uncover Kodiak Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kodiak Sciences include Jazz Pharmaceuticals, argenx and Alexion. Here is the list of Top 10 competitors of Kodiak Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
73rd	Kodiak Sciences 2009, Palo Alto (United States), Public	Developer of therapeutics to treat retinal diseases	$35.8M	ArrowMark Partners, Perceptive Advisors & 1 others	64/100